|
|
Post by harryx1 on Apr 5, 2019 12:45:09 GMT -5
|
|
|
|
Post by kite on Apr 5, 2019 12:46:58 GMT -5
|
|
|
|
Post by agedhippie on Apr 5, 2019 14:24:51 GMT -5
Let me. The chart is pretty much meaningless for comparative pricing since the unit sizes are all over the place. What they are looking at is the amount the price haas increased by for each insulin product. Because you are looking at the increase in cost from the 2016 base the unit size doesn't really matter. The chart says the price of Afrezza has increased by twice as much as anyone else. That said, I didn't know it was available in on Medicare in 2016 which makes me wonder about their data. |
|
|
|
Post by mnkdfann on Apr 5, 2019 16:36:25 GMT -5
Let me. The chart is pretty much meaningless for comparative pricing since the unit sizes are all over the place. What they are looking at is the amount the price haas increased by for each insulin product. Because you are looking at the increase in cost from the 2016 base the unit size doesn't really matter. The chart says the price of Afrezza has increased by twice as much as anyone else. That said, I didn't know it was available in on Medicare in 2016 which makes me wonder about their data. Check the discussion following Figure 5 in the report at the original link, and don't miss the Tables in the Appendix. Specifically, Table 2 that gives Average Spending per Claim. Actually, I may as well just post the link to the Tables: www.kff.org/report-section/how-much-does-medicare-spend-on-insulin-tables/ |
|
